Targeting interleukin-4 and interleukin-13 in the treatment of severe eosinophilic asthma
<p>Asthma is a chronic inflammatory airway disease affecting about 300 million people and responsible for 500,000 deaths annually globally. Eosinophilic asthma is one of the most common phenotypes of asthma. It constitutes about 50% to 60% of all cases of asthma, and it is the most common phen...
Saved in:
Main Author: | Nightingale Syabbalo (Author) |
---|---|
Format: | Book |
Published: |
Archives of Pulmonology and Respiratory Care - Peertechz Publications,
2023-02-02.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets
by: Corrado Pelaia, et al.
Published: (2022) -
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
by: Pelaia C, et al.
Published: (2017) -
Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
by: Yuliya Lytvyn, et al.
Published: (2023) -
The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma
by: Giancarlo Marone, et al.
Published: (2019) -
Interleukin-5 modulates interleukin-8 secretion in eosinophilic inflammation
by: L. H. Faccioli, et al.
Published: (1998)